Posted by Michael Wonder on 20 Oct 2024
Prostate cancer: significant additional benefit for PSMA diagnostics with gozetotide
15 October 2024 - Because of the direct link between diagnosis and therapy, the data from the early benefit assessment of the therapeutic agent lutetium Lu 177 can be used for the evaluation of gozetotide.
Gozetotide is a diagnostic agent for use in adults with prostate cancer. It is the only diagnostic agent to date that detects PSMA positive prostate cancer and can thus identify patients who are candidates for PSMA targeted therapy with lutetium Lu177 vipivotide tetraxetan.
